Sinopharm Group Co Stock Analysis
| SHTDF Stock | USD 2.35 0.00 0.00% |
Sinopharm Group holds a debt-to-equity ratio of 0.894. Sinopharm Group's financial risk is the risk to Sinopharm Group stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Sinopharm Group's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Sinopharm Group's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Sinopharm Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Sinopharm Group's stakeholders.
For most companies, including Sinopharm Group, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Sinopharm Group Co, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Sinopharm Group's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Sinopharm Group's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Sinopharm Group is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Sinopharm Group to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Sinopharm Group is said to be less leveraged. If creditors hold a majority of Sinopharm Group's assets, the Company is said to be highly leveraged.
Sinopharm Group Co is overvalued with Real Value of 2.03 and Hype Value of 2.35. The main objective of Sinopharm Group pink sheet analysis is to determine its intrinsic value, which is an estimate of what Sinopharm Group Co is worth, separate from its market price. There are two main types of Sinopharm Group's stock analysis: fundamental analysis and technical analysis.
The Sinopharm Group pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Sinopharm Group's ongoing operational relationships across important fundamental and technical indicators.
Sinopharm |
Sinopharm Pink Sheet Analysis Notes
About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sinopharm Group last dividend was issued on the 27th of June 2022. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd. Sinopharm Group is traded on OTC Exchange in the United States.The quote for Sinopharm Group Co is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Sinopharm Group Co contact the company at 86 21 2305 2666 or learn more at https://www.sinopharmgroup.com.cn.Sinopharm Group Investment Alerts
| Sinopharm Group generated a negative expected return over the last 90 days |
Sinopharm Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sinopharm Group's market, we take the total number of its shares issued and multiply it by Sinopharm Group's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Sinopharm Profitablity
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.Technical Drivers
As of the 31st of January, Sinopharm Group has the Coefficient Of Variation of (1,172), variance of 1.07, and Risk Adjusted Performance of (0.06). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sinopharm Group, as well as the relationship between them. Please validate Sinopharm Group market risk adjusted performance, variance, as well as the relationship between the Variance and skewness to decide if Sinopharm Group is priced more or less accurately, providing market reflects its prevalent price of 2.35 per share. Please also confirm Sinopharm Group Co information ratio, which is currently at (0.14) to double-check the company can sustain itself at a future point.Sinopharm Group Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Sinopharm Group middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Sinopharm Group. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Sinopharm Group Predictive Daily Indicators
Sinopharm Group intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sinopharm Group pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sinopharm Group Forecast Models
Sinopharm Group's time-series forecasting models are one of many Sinopharm Group's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sinopharm Group's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Sinopharm Group Debt to Cash Allocation
Many companies such as Sinopharm Group, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Sinopharm Group Co has accumulated 8.42 B in total debt with debt to equity ratio (D/E) of 0.89, which is about average as compared to similar companies. Sinopharm Group has a current ratio of 1.28, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sinopharm Group until it has trouble settling it off, either with new capital or with free cash flow. So, Sinopharm Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinopharm Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinopharm to invest in growth at high rates of return. When we think about Sinopharm Group's use of debt, we should always consider it together with cash and equity.Sinopharm Group Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Sinopharm Group's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Sinopharm Group, which in turn will lower the firm's financial flexibility.About Sinopharm Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Sinopharm Group prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sinopharm shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Sinopharm Group. By using and applying Sinopharm Pink Sheet analysis, traders can create a robust methodology for identifying Sinopharm entry and exit points for their positions.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd. Sinopharm Group is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Sinopharm Group to your portfolios without increasing risk or reducing expected return.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Complementary Tools for Sinopharm Pink Sheet analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |